The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 30, 2018

Filed:

Jun. 19, 2017
Applicant:

Magenta Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Andrew Nixon, Hanover, MA (US);

Dwight Morrow, West Chester, PA (US);

Adam Hartigan, Brookline, MA (US);

Assignee:

Magenta Therapeutics, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61K 35/28 (2015.01);
U.S. Cl.
CPC ...
A61K 47/6849 (2017.08); A61K 35/28 (2013.01); A61K 47/6803 (2017.08); A61K 47/6809 (2017.08); A61K 47/6811 (2017.08); A61K 47/6817 (2017.08); A61K 47/6829 (2017.08); A61K 47/6831 (2017.08); C07K 16/2803 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/55 (2013.01); Y02A 50/401 (2018.01); Y02A 50/414 (2018.01);
Abstract

The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.


Find Patent Forward Citations

Loading…